
Indian pharma makes a strategic shift to innovate generics via 505(b)(2) to carve a global niche: Dr Hemgir Gosavi
Indian pharma companies are moving away from merely supplying me-too versions of blockbuster drugs. Instead, these companies are increasingly leveraging the US FDA’s 505(b)(2) regulatory




